The incidence of heroin abuse has been increasing steadily over the past few years, and will most likely continue to increase, with non-injection routes becoming more popular. Although treatment medications (such as methadone, levo-alpha-acetylmethadol (LAAM), and naltrexone) for opiate dependence currently exist, many problems are associated with their use such as patient noncompliance, continued opiate use during treatment, and high relapse rates during withdrawal from treatment. Several possible causes for these problems have been suggested but insufficient research has been conducted to evaluate the effects of these medications on ongoing human behavior in a research laboratory setting. In the proposed research, opiate-dependent male and female subjects residing in a controlled setting will be given the opportunity to work for smoked heroin or money in both the presence and absence of a treatment medication. These studies will examine the multiplicity of ways in which these medications affect ongoing human behavior including effects on heroin consumption, performance, mood, social behavior, food consumption, physiological measures, tobacco and caffeine consumption, and subjects' verbal reports of drug effects. The model thus developed will be used to evaluate potential new medications for opiate abuse as they are developed and before they are put into time consuming and expensive multi-center trials.
The specific aims of the proposal are: 1) the development of a model of smoked heroin self-administration in humans under controlled conditions to evaluate patterns of heroin self-administration, as well as doses of heroin that are used; 2) an analysis of the similarities and differences between i.v. and smoked heroin on physiological, subjective- effects, and performance measures; 3) the development of a model for evaluating both existing and potential new treatment medications on heroin self-administration, as well as other ongoing behaviors; 4) evaluation of whether narcotic antagonists, at the doses that are currently used, are effective with the newly potent street heroin; and 5) development and validation of this model for the evaluation of potential new medications in an efficient and safe fashion.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009236-03
Application #
2374089
Study Section
Project Start
Project End
Budget Start
1995-10-01
Budget End
1996-09-30
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Brezing, Christina A; Choi, C Jean; Pavlicova, Martina et al. (2018) Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Am J Addict 27:101-107
Cooper, Ziva D; Bedi, Gillinder; Ramesh, Divya et al. (2018) Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology 43:2046-2055
Chao, Thomas; Radoncic, Vanya; Hien, Denise et al. (2018) Stress responding in cannabis smokers as a function of trauma exposure, sex, and relapse in the human laboratory. Drug Alcohol Depend 185:23-32
Metz, Verena E; Sullivan, Maria A; Jones, Jermaine D et al. (2017) Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. J Psychoactive Drugs 49:59-68
Metz, Verena E; Jones, Jermaine D; Manubay, Jeanne et al. (2017) Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 42:1825-1832
Vadhan, Nehal P; Corcoran, Cheryl M; Bedi, Gill et al. (2017) Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study. Psychiatry Res 257:372-374
Bachtell, Ryan K; Jones, Jermaine D; Heinzerling, Keith G et al. (2017) Glial and neuroinflammatory targets for treating substance use disorders. Drug Alcohol Depend 180:156-170
Babalonis, Shanna; Haney, Margaret; Malcolm, Robert J et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9-13
Cooper, Ziva D; Johnson, Kirk W; Pavlicova, Martina et al. (2016) The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol 21:895-903
Herrmann, Evan S; Cooper, Ziva D; Bedi, Gillinder et al. (2016) Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl) 233:2469-78

Showing the most recent 10 out of 129 publications